Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 11/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5400194 | 0.87 | ALOX5 (0.51) | LTA4HL3MBTL1EPHX2TDP1ALDH1A1 | |
| SCHEMBL6105604 | 0.87 | ALOX5 (0.51) | LTA4HL3MBTL1EPHX2TDP1ALDH1A1 | |
| SCHEMBL8989000 | 0.87 | L3MBTL1 (0.47) | LTA4HNAAAL3MBTL1EPHX2TDP1 | |
| SCHEMBL8743036 | 0.86 | LTA4H (0.54) | LTA4HL3MBTL1EPHX2TDP1ALDH1A1 | |
| SCHEMBL31260990 | 0.86 | EPHX2 (0.47) | LTA4HNAAAL3MBTL1EPHX2PPID | |
| SCHEMBL9212182 | 0.85 | ALOX5 (0.52) | LTA4HL3MBTL1EPHX2TDP1ALDH1A1 | |
| SCHEMBL24675914 | 0.84 | L3MBTL1 (0.45) | LTA4HNAAAL3MBTL1EPHX2TDP1 | |
| SCHEMBL21069070 | 0.84 | L3MBTL1 (0.45) | LTA4HNAAAL3MBTL1EPHX2TDP1 | |
| SCHEMBL21068723 | 0.84 | L3MBTL1 (0.45) | LTA4HNAAAL3MBTL1EPHX2TDP1 | |
| SCHEMBL21069058 | 0.84 | L3MBTL1 (0.45) | LTA4HNAAAL3MBTL1EPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | HORST P.O. WOLF (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6013666-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | Jew, Sang Sup (KR) | 2000-01-11 | — | — | US | disclosed |
| WO-1998000422-A1 | OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD | JEW SANG SUP (KR) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | GPR119, SLC5A2, SLC2A4 | LTA4H 860/4885NAAA 1110/4885L3MBTL1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.